openPR Logo
Press release

Fibroblast Activation Protein Inhibitors Market : Increase in Government Initiative to Boost the Market by 2024

01-16-2020 01:12 PM CET | Health & Medicine

Press release from: TMR

Fibroblast Activation Protein Inhibitors Market

Fibroblast Activation Protein Inhibitors Market

Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed on stromal fibroblasts of epithelial cancer cells and promotes cancer cell growth and metastasis.

View Report: https://www.transparencymarketresearch.com/fibroblast-activation-protein-inhibitors-market.html

The specificity of fibroblast activation protein offers potential to represent as a new drug target in the diagnosis and treatment of cancer. Various clinical trials are being conducted to assess the potential of treating cancer by inhibiting the fibroblast activation protein. Cancer cells are often very sensitive to growth factors. Development of cancer growth impeders such as fibroblast activation protein (FAP) inhibitors can provide promising results in cancer management.

Fibroblast activation protein (FAP) have similar specificity as dipeptidyl peptidases (DPPs) and prolyl oligopeptidase (PREP) which are also known to elevate in cancers. This leads to the need of development of inhibitors that are specific to fibroblast activation protein (FAP).

Huge opportunities lie in development of fibroblast activation protein (FAP) specific inhibitors. Vigorous research and development programs are being conducted for the development of such inhibitors. One such inhibitor is Val-boroPro (Talabostat) which is a single-agent inhibitor of fibroblast activation protein (FAP) enzymatic activity. A number of clinical trials have been conducted to assess the efficacy of talabostat as fibroblast activation protein (FAP) inhibitor in different cancers such as colorectal, lung, pancreatic, leukemia and melanoma. Another approach being used in developing fibroblast activation protein (FAP) inhibitor is monoclonal antibodies. However, such approaches have not been extensively used in the clinical setting, mainly due to absence of effective actions.

Due to the rise in the prevalence of cancer globally, fibroblast activation protein (FAP) inhibitors are anticipated to assist in prevention of proliferation of these carcinogenic cells. According to the National Cancer Institute, an estimated 1,685,210 new cases of cancer will be detected in 2016 in the U.S alone. The most common ones are breast cancer, prostate cancer, colon and rectum cancer, lung and bronchus cancer, bladder cancer, melanoma, kidney and renal pelvis cancer, leukemia, and pancreatic cancer. Of these colorectal cancer is the third most common type of cancer in the world. This cancer is a result of uninhibited cell progression that occurs in the appendix, colon, and the rectum region. The common symptoms of colorectal cancer are bleeding in the stool, weight loss, fatigue, and irregular bowel movements. According to the World Cancer Research Fund International, approximately 1.5 million new cases of colorectal cancer are detected each year. Many clinical trials are being conducted to discover novel methods to treat colorectal cancer through fibroblast activation protein (FAP) inhibitors.

Request PDF Brochure of the Fibroblast Activation Protein Inhibitors Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14159

The increasing worldwide prevalence of various cancers, including breast cancer, colorectal cancer, prostate cancer, skin cancer, blood cancer, gastrointestinal tract cancer, and lung cancer, is the prime factor heightening the demand for anti-cancer drugs. In addition to this, the improvement of advanced therapeutic approaches, such as targeted therapies, immunotherapy, radiotherapy, and chemotherapy has significantly benefited the anti-cancer drugs market in recent years. Although not much progress has been made in fibroblast activation protein (FAP) inhibitors discovery for treating various cancer, this field possesses huge research and development opportunities in the near future.

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Fibroblast Activation Protein Inhibitors Market : Increase in Government Initiative to Boost the Market by 2024 here

News-ID: 1898226 • Views: 109

More Releases from TMR

Capacitor Market to Offer Ample Growth Opportunities by 2031, TMR Study
The global Capacitor market is estimated to attain a valuation of US$ 58.67 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 6.4% during the forecast period, 2022 to 2022. TMR Research report on the Capacitor market stands out from others due to the experience of the TMR experts. The market
Microgrid-as-a-Service Market to Witness Growth Acceleration During 2022 - 2031, …
The global Microgrid-as-a-Service market is estimated to attain a valuation of US$ 7.83 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 15.7% during the forecast period, 2022 to 2022. TMR Research report on the Microgrid-as-a-Service market stands out from others due to the experience of the TMR experts. The market
Quartz Crystal Market is Set To Garner Staggering Revenues By 2031, TMR Study
The global Quartz Crystal market is estimated to attain a valuation of US$ 8.83 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 6.8% during the forecast period, 2022 to 2022. TMR Research report on the Quartz Crystal market stands out from others due to the experience of the TMR experts.
Ultraviolet (UV) Analyzer Market Projected To Garner Significant Revenues By 203 …
The global Ultraviolet (UV) Analyzer market is estimated to attain a valuation of US$ 3.6 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 5.7% during the forecast period, 2022 to 2022. TMR Research report on the Ultraviolet (UV) Analyzer market stands out from others due to the experience of the

All 5 Releases


More Releases for FAP

Fibroblast Activation Protein Inhibitors Market Research Report | Forecast Until …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Read Report Overview - https://www.transparencymarketresearch.com/fibroblast-activation-protein-inhibitors-market.html Fibroblast activation protein is widely
Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018
Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person. Download the sample report at: https://www.pharmaproff.com/request-sample/1025 A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated
Fibroblast Activation Protein Inhibitors Market to Witness a Pronounce Growth by …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed
Fibroblast Activation Protein Inhibitors Market Dynamics, Forecast, Analysis and …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed
Fibroblast Activation Protein Inhibitors Industry: Global Survey, Trends, Outloo …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed
Fibroblast Activation Protein Inhibitors Market Set to Surge Significantly by 20 …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed